Every 10-Q that Advanced Biomed Inc. (ADVB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ADVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADVB filings page.
Advanced Biomed Inc. reported net income of $5,982,078 for the nine months ended March 31, 2026, driven mainly by a one-time gain of $7,346,684 from selling its Hong Kong subsidiary and related clinical operations. From continuing operations, the company earned $6,254,557 over nine months but posted a quarterly loss of $488,942, reflecting ongoing R&D and administrative costs.
Cash from continuing operations was $2,602,697 at March 31, 2026, with net cash used in operating activities of $1,363,675. Management discloses substantial doubt about the company’s ability to continue as a going concern and highlights reliance on new funding, including a January 2026 private placement raising $248,000 and an equity line facility of up to $25,000,000. The company executed a 1‑for‑20 reverse stock split and had 1,382,133 shares outstanding as of March 31, 2026.
Advanced Biomed Inc. reported net income of $6.47M for the six months ended December 31, 2025, a sharp improvement from a prior-year loss. This turnaround was driven almost entirely by a $7.35M gain on selling its Hong Kong subsidiary and related China operations, which are now classified as discontinued.
From continuing operations the company generated income of $6.74M, while discontinued operations produced a loss of $0.27M. Operating expenses remained modest at $0.79M over six months, reflecting a lean cost base focused on research and development and general and administrative activities.
Despite the reported profit, Advanced Biomed used $1.12M of cash in operating activities and ended the period with cash of $2.60M. Total assets were $10.85M and total liabilities fell to $1.37M, leaving stockholders’ equity of $9.48M, largely helped by the deconsolidation gain.
Management disclosed that the positive earnings are mainly one-time and that recurring operations still consume cash, leading to “substantial doubt” about the company’s ability to continue as a going concern. To support liquidity, Advanced Biomed highlighted its prior IPO and a $25M equity line of credit agreement with an institutional investor, as well as subsequent share issuances in January 2026.
Advanced Biomed Inc. (ADVB) reported a continued operating loss as it advances oncology diagnostics development. For the three months ended September 30, 2025, the company recorded a net loss of $386,901, wider than $265,580 a year earlier, driven mainly by higher research and development spending.
Total operating expenses were $523,914, including $235,992 for research and development and $287,922 for general and administrative costs. Other income, largely foreign exchange gains, added $137,013, partially offsetting expenses. There was no income tax expense.
As of September 30, 2025, Advanced Biomed held cash of $2,656,519 and total assets of $6,242,970, against total liabilities of $3,238,846 and stockholders’ equity of $3,004,124. Operating activities used $610,342 of cash in the quarter. Management discloses substantial doubt about the company’s ability to continue as a going concern but notes support from its March 2025 IPO, which raised $6.56 million in gross proceeds, and an equity line of credit allowing sales of up to $25,000,000 of common stock.